Increasing demand and regulatory approvals are boosting the manufacture and commercialisation of cell and gene therapies, but what are the challenges affecting their supply chain? What preparations need to be made for effective delivery of these advanced therapies at national and global scales? Anna Outhwaite, head of ATTC network coordination has been interviewed by KNEct 365, ahead of talking  at Cell and Gene Therapy: Bioprocessing and Commercialization (September 9-12, 2019, Boston)  about how the ATTC programme  is looking at the supply chain and the complex challenges posed by it.

INDUSTRY VOICES: Tackling the downstream supply chain challenges of cell and gene therapies